These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9861295)

  • 1. Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease?
    Rabelink TJ; Stroes ES; Bouter KP; Morrison P
    Cardiovasc Res; 1998 Sep; 39(3):543-9. PubMed ID: 9861295
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prospects for endothelin-related drugs].
    Goto K
    Nihon Rinsho; 2004 Sep; 62 Suppl 9():673-81. PubMed ID: 15506472
    [No Abstract]   [Full Text] [Related]  

  • 3. Neutral endopeptidase inhibition: the potential of a new therapeutic approach in cardiovascular disease evolves.
    Veelken R; Schmieder RE
    J Hypertens; 2002 Apr; 20(4):599-603. PubMed ID: 11910290
    [No Abstract]   [Full Text] [Related]  

  • 4. Multitarget cardiovascular drugs.
    Trstenjak U; Kikelj D
    Curr Med Chem; 2011; 18(17):2531-42. PubMed ID: 21568894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Endothelin and kidney disease].
    Nakayama Y; Tomita K
    Nihon Rinsho; 2004 Sep; 62 Suppl 9():655-60. PubMed ID: 15506468
    [No Abstract]   [Full Text] [Related]  

  • 6. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases.
    Daull P; Jeng AY; Battistini B
    J Cardiovasc Pharmacol; 2007 Sep; 50(3):247-56. PubMed ID: 17878751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system.
    Doggrell SA
    Expert Opin Investig Drugs; 2002 Nov; 11(11):1537-52. PubMed ID: 12437501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Of mice and men: advances in endothelin research and first antagonist gains FDA approval.
    Davenport AP; Maguire JJ
    Trends Pharmacol Sci; 2002 Apr; 23(4):155-7. PubMed ID: 11931980
    [No Abstract]   [Full Text] [Related]  

  • 9. Renoprotective effects of renin-angiotensin-system inhibitors.
    de Zeeuw D; Lewis EJ; Remuzzi G; Brenner BM; Cooper ME
    Lancet; 2006 Mar; 367(9514):899-900; author reply 900-2. PubMed ID: 16546533
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of the pharmacological effects of endothelin.
    Wilson C; Hargreaves RB
    Prog Med Chem; 1994; 31():371-410. PubMed ID: 8029479
    [No Abstract]   [Full Text] [Related]  

  • 11. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?
    Kirkby NS; Hadoke PW; Bagnall AJ; Webb DJ
    Br J Pharmacol; 2008 Mar; 153(6):1105-19. PubMed ID: 17965745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of endothelin-converting enzyme inhibitors for the treatment of cardiovascular diseases.
    Jeng AY
    Curr Opin Investig Drugs; 2003 Sep; 4(9):1076-81. PubMed ID: 14582451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin antagonism in pulmonary hypertension, heart failure, and beyond.
    Attinà T; Camidge R; Newby DE; Webb DJ
    Heart; 2005 Jun; 91(6):825-31. PubMed ID: 15894792
    [No Abstract]   [Full Text] [Related]  

  • 15. Endothelin-converting enzyme inhibitors for the treatment of subarachnoid hemorrhage-induced vasospasm.
    Lin CL; Winardi W; Jeng AY; Kwan AL
    Neurol Res; 2006 Oct; 28(7):721-9. PubMed ID: 17164035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Trend of research and development of antihypertensive agents].
    Imura Y
    Nihon Rinsho; 2006 Jul; 64 Suppl 5():583-7. PubMed ID: 16895229
    [No Abstract]   [Full Text] [Related]  

  • 17. Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be?
    Hollenberg NK; Epstein M
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1046-8. PubMed ID: 17699325
    [No Abstract]   [Full Text] [Related]  

  • 18. Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage.
    Sharkovska Y; Kalk P; von Websky K; Relle K; Pfab T; Alter M; Fischer Y; Hocher B
    Clin Lab; 2011; 57(7-8):507-15. PubMed ID: 21888014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs.
    Lüscher TF; Barton M
    Circulation; 2000 Nov; 102(19):2434-40. PubMed ID: 11067800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications.
    Jeng AY; Mulder P; Kwan AL; Battistini B
    Can J Physiol Pharmacol; 2002 May; 80(5):440-9. PubMed ID: 12056551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.